Paula M Lorenzini

Plain English
This study looked at the effects of a combination treatment of amivantamab and lazertinib on patients with advanced lung cancer that has unusual mutations in a specific gene. Among 105 patients treated, 52% had a positive response, meaning the treatment helped shrink their tumors, and the response lasted an average of 14.1 months. This is important because it offers an effective option for patients who do not respond well to existing therapies, improving their chances of extended survival and better quality of life. Who this helps: This benefits patients with advanced non-small cell lung cancer who have atypical mutations.

Plain English
This study looked at how well a new treatment called amivantamab combined with chemotherapy works for patients in Asia who have a specific type of advanced lung cancer caused by EGFR exon 20 mutations. The researchers found that patients who received amivantamab with chemotherapy experienced significantly longer periods without their cancer worsening—11.5 months compared to 5.6 months for those who only got chemotherapy. Additionally, 70% of patients in the amivantamab group responded positively to the treatment, compared to 51% in the chemotherapy-only group. Who this helps: Patients with EGFR exon 20 mutation lung cancer benefit from this new treatment option.

Plain English
This study looked at how well a new drug, amivantamab, combined with chemotherapy, works compared to chemotherapy alone for patients with a specific type of advanced lung cancer that is hard to treat. Researchers found that after one year, 77% of patients treated with amivantamab and chemotherapy did not experience worsening symptoms, compared to 60% of those on chemotherapy alone. This is important because it shows that the new treatment not only helps patients live longer without their cancer getting worse but also maintains their quality of life. Who this helps: This benefits patients with EGFR exon 20 insertion-mutated advanced non-small cell lung cancer.

Plain English
This study looked at whether changing HIV treatment from a combination of efavirenz, emtricitabine, and tenofovir disoproxil fumarate to bictegravir, emtricitabine, and tenofovir alafenamide could help improve mental health and brain function. Out of 126 people with HIV, those who switched reported reduced anxiety, depression, and better sleep quality, but brain function remained mostly the same with only slight declines in some areas. This matters because finding effective treatments that improve overall well-being is crucial for people living with HIV. Who this helps: Patients living with HIV looking for better treatment options that also address mental health.

Plain English
This study looked at two methods for preparing patients for early morning colonoscopies: taking all the preparation the night before versus splitting the preparation into two doses, one taken the night before and another a few hours before the procedure. Researchers found that the night-before method was effective for 88.2% of patients compared to 98.1% for the split-dose method; however, it was less effective overall, especially for procedures scheduled between 8 am and 10 am, despite being more comfortable for some patients. The findings suggest that while the night-before method is not as effective in general, it could be a good option for very early morning procedures where it performed similarly to the split-dose method. Who this helps: This benefits patients preparing for early morning colonoscopies, especially those who may be anxious about the split-dose regimen.

Plain English
This research reviewed studies on the oral microbiome, which is the community of bacteria and fungi in our mouths, and how it relates to aging. It found that while most oral bacteria and fungi stay about the same as people get older, older adults tend to have more harmful bacteria associated with gum disease. Additionally, the variety of different bacteria decreases with age. This information is important because it may lead to better understanding how oral health affects overall health in older people. Who this helps: This helps elderly patients by highlighting the importance of oral health in aging.

Plain English
This study looked at how Italy has responded to the growing issue of dementia, with around 2 million people affected in the country. From 2021 to 2023, the Italian Fund for Alzheimer's and other Dementias coordinated various initiatives, leading to the mapping of memory clinics and care facilities, and revealing that 39.5% of dementia cases might be preventable through lifestyle changes. This information is crucial because it shows that by improving care services and addressing regional inequalities, Italy can set an example for other countries facing similar challenges. Who this helps: Patients and caregivers dealing with dementia.

Plain English
This study looked at the experiences of caregivers for people with dementia in Italy, especially how the COVID-19 pandemic affected their well-being. It surveyed 2,369 caregivers and found that many were women (73.4%) and often the children of the people they cared for (74.1%). Satisfaction with dementia care services was only "acceptable," with significant dissatisfaction linked to factors like caregiver age, lack of training, and where they lived. Who this helps: This benefits caregivers and families of people living with dementia by highlighting their needs for better support and services.

Plain English
This study examined how soy lecithin affects the texture and stability of plant-based egg custard alternatives made from lupin protein. They found that adding 1% lecithin changes the gel strength of the custard depending on the acidity; at pH 6, the strength was highest (5.47 kPa·s) but dropped significantly at pH 8 (0.783 kPa·s). This matters because it shows that whether lecithin is used can determine the final product's texture and overall quality, making these custard mimics a potential nutritious alternative to eggs. Who this helps: This benefits food companies looking to create better plant-based alternatives for consumers.

Plain English
This study focused on how multiciliated cells (MCCs) create numerous centrioles needed for their cilia, which help move fluids in the body. Researchers found that a key protein called MCIDAS helps manage the production of these centrioles by moving from the nucleus to the cytoplasm, and when MCIDAS was disrupted, it reduced the creation of new centrioles significantly. This discovery is important because understanding this process could help explain certain diseases related to cilia, known as motile ciliopathies. Who this helps: This helps researchers and doctors working with patients who have cilia-related diseases.

Plain English
This study looked at the healthcare needs of older adults with chronic diseases by using a tool called the BRIEF-Multidimensional Prognostic Index (BRIEF-MPI) to create personalized prevention programs. Researchers assessed 612 participants and found that 59% had significant issues with multiple medications, 25% were malnourished or obese, and many were missing important vaccinations—like 89% who hadn't received the herpes zoster vaccine. This is important because it helps doctors better understand and address the specific health challenges faced by older adults, ultimately leading to improved care and outcomes. Who this helps: Older adults with chronic health conditions.

Plain English
This study looked at how certain forms of the influenza A virus, called deletion-containing viral genomes (DelVGs), interact with standard viral genomes (WT) during replication. The researchers found that in a controlled environment, a wide variety of DelVGs initially appeared, but over time, just one or two types became dominant, particularly those that had a specific genetic change allowing them to replicate better and compete against WT genomes. Understanding these changes is important because it shows how DelVGs can influence the severity of flu infections and the overall behavior of the virus. Who this helps: This information benefits doctors and researchers working to understand and treat influenza infections.

Plain English
Researchers conducted a survey in Italy to examine the characteristics and available services at Day Care Centers for people with dementia during the COVID-19 pandemic. Out of 1,084 centers, only 443 (41%) responded to basic questions, and 300 (27.7%) provided more detailed information. The study found that most centers (88.5%) were privately owned, especially in northern Italy, and only 6% remained open throughout 2020; this increased to 48% in 2021, revealing significant variation in center operations based on location and pandemic impacts. Who this helps: This information benefits patients with dementia and their families, as well as healthcare providers and policymakers.

Plain English
This study looked at how a specific type of infection in zebrafish, caused by Mycobacterium marinum, can make it easier for another bacteria called Mycobacterium abscessus to thrive. The researchers found that M. abscessus grows preferentially in the granulomas created by M. marinum, avoiding the immune response and antibiotics, which means it can survive and multiply there. This matters because it shows how one infection can set the stage for another, potentially more dangerous infection to take hold. Who this helps: This helps patients with tuberculosis and healthcare providers managing complex infections.

Plain English
This study looked at how well Italy is following national guidelines for dementia care by evaluating 39 integrated care pathways (ICPs) across the country. The findings showed that these pathways are generally not meeting the expected standards, with an average score of 23.5 out of 43 for regional authorities and 23.1 for local health authorities, indicating a need for better compliance and monitoring. Improving these pathways is crucial for ensuring that people with dementia receive the high-quality care they deserve. Who this helps: This helps patients with dementia and their caregivers.

Plain English
This study explored the experiences of family members and caregivers of people with dementia, as well as health and social care professionals in Italy. Researchers held 42 group discussions with 329 participants, revealing that many caregivers struggle with inconsistent and inadequate services, and often feel overwhelmed. The study highlighted that specialized dementia care services are vital and called for better training for professionals, public awareness to combat stigma, and more cohesive support to ensure that families receive the help they need. Who this helps: This benefits patients with dementia and their family caregivers.

Plain English
Researchers studied the effectiveness of amivantamab, a new treatment, in patients with advanced lung cancer who have specific genetic mutations known as MET exon 14 skipping mutations. Out of 97 patients, 32% had a positive response to the treatment overall, with a higher response of 50% in those who had not been treated before. This treatment is important because it shows promise for patients who have not responded to other therapies, with an average overall survival of 15.8 months. Who this helps: This benefits patients with advanced NSCLC and MET exon 14 skipping mutations.

Plain English
This research looked at centers in Italy that help people with cognitive disorders and dementia, especially during the COVID-19 pandemic. It found that while 96% of these centers provided information, only about one-third were continuously open in 2020, improving to two-thirds in 2021. This matters because it highlights both the challenges these centers faced and the urgent need to improve care and diagnosis for patients with dementia. Who this helps: This helps patients with dementia and their families.

Plain English
This study compared two ways of administering the cancer drug amivantamab—through a needle under the skin (subcutaneous) versus through an IV (intravenous)—for patients with advanced lung cancer who had already tried other treatments. The results showed that the under-the-skin method was just as effective as the intravenous one, with a similar survival rate; the subcutaneous group had a median survival of about 6.1 months compared to 4.3 months for the intravenous group. Importantly, fewer patients experienced harmful reactions with the subcutaneous method, and it took much less time to administer (about 5 minutes compared to 5 hours). Who this helps: This benefits lung cancer patients looking for more manageable and effective treatment options.

Plain English
This study looked at a combination treatment of amivantamab and lazertinib for patients with advanced non-small-cell lung cancer (NSCLC) who had a specific genetic mutation. It found that patients treated with this combination lived longer without cancer progression—about 23.7 months compared to 16.6 months for those on another treatment, osimertinib. Additionally, 86% of patients on the combination showing a positive response to treatment, which is similar to the 85% for osimertinib, but the response lasted longer with the combination. Who this helps: This benefits patients with advanced NSCLC who have specific mutations, providing them with more effective treatment options.

Plain English
This study focuses on creating a tool to predict which people with mild cognitive impairment (MCI) will develop Alzheimer's disease within three years. Researchers enrolled 500 individuals aged 50-85 and examined various tests and markers, such as brain scans and cognitive assessments, to identify patterns that indicate higher risk. The findings will help doctors identify high-risk patients who may benefit from new therapies aimed at preventing Alzheimer's. Who this helps: This helps patients with mild cognitive impairment and their doctors make informed decisions about treatment.

Plain English
This study examined Italian Centers for Cognitive Disorders and Dementia to see how prepared they are to prescribe new Alzheimer’s drugs. It found that only 10.4% of these centers meet the necessary criteria for effective prescriptions, mostly those in Northern Italy, which typically have better resources and staff. Improving the readiness of these centers is crucial for providing better care to Alzheimer’s patients as new treatments become available. Who this helps: Patients with Alzheimer's disease and their families.

Plain English
This study looked at a personalized prevention program designed for older adults with chronic health conditions to see if it could reduce unexpected hospital visits over a year. In total, 1,216 older people participated, with those in the program receiving support for improving their daily functioning, nutrition, and social connections. The findings will help determine if this program can make a real difference in preventing hospitalizations and improving quality of life for older adults. Who this helps: Older adults with chronic health issues.

Plain English
This study looked at how neuropsychological tests are used in Italian centers that focus on cognitive disorders and dementia. Researchers found that the percentage of these centers using a basic set of tests increased from 45.7% in 2015 to 57.1% in 2022, but nearly 43% still do not use these tests. The findings highlight the importance of having trained psychologists on staff, as centers with these professionals are more likely to use the recommended tests, which are critical for accurate diagnosis and targeted treatment. Who this helps: This helps patients and healthcare providers in improving dementia diagnosis and care.

Plain English
This study looked at the occurrence of neurocognitive disorders linked to HIV in a large group of patients receiving treatment between 2009 and 2020. The research found that 24% of treated individuals had these disorders, but this percentage dropped significantly over the years, particularly among those who reported cognitive issues. The study highlights that factors like older age or lower education levels increase the risk of these disorders, while newer treatment methods, particularly integrase inhibitors, are associated with a lower risk. Who this helps: This benefits patients living with HIV, as well as their healthcare providers.

Plain English
This study looked at how effective a combination treatment of dolutegravir and lamivudine is for people living with HIV who already have an undetectable viral load but had experienced previous treatment failures. Out of 966 participants, only 23 experienced a viral rebound. The one-year risk of this happening was 1.2% for those without any treatment failures and 3.3% for those with at least one previous failure, indicating that past treatment issues increase the risk of a rebound in viral levels. Who this helps: This research benefits people living with HIV and their doctors by providing insights on managing treatment options effectively.

Plain English
This study looked at a gene called CR1, which plays a role in how malaria parasites invade red blood cells, potentially leading to severe cases of malaria. Researchers found that certain populations in malaria-prone areas, like East India and Papua New Guinea, had positive adaptations in the CR1 gene that help them resist the disease. They identified specific genetic variants linked to lower CR1 expression, which may protect against malaria's severe forms, showing important differences in how various populations adapt to this deadly disease. Who this helps: This helps patients in malaria-endemic regions by providing insights into genetic factors that may offer protection against severe malaria.

Plain English
This study focused on how to manage infusion-related reactions (IRRs) in patients receiving a cancer treatment called amivantamab, which is used for a type of lung cancer. Out of 380 patients treated, 67% (256 patients) experienced IRRs, mostly mild symptoms like chills and nausea, but only a few had severe reactions. The findings highlight that most IRRs happen right after the first infusion, and effective management strategies can help ensure that patients can continue their treatment safely. Who this helps: This benefits lung cancer patients receiving amivantamab and their healthcare providers.

Plain English
This study looked at the effectiveness of a medication called sarilumab, combined with standard treatment, for adults with severe COVID-19 who were not on ventilators. They found that after 30 days, about 88% of patients receiving sarilumab saw improvement, compared to 85% in the group receiving standard care alone, showing no significant difference overall. However, some patients with lower levels of inflammation or certain blood counts may have benefited more from sarilumab, so more research is needed to confirm this. Who this helps: This may benefit patients with severe COVID-19, especially those with specific inflammatory markers.

Plain English
This study looked at how post-COVID-19 syndrome affects the quality of life for patients up to a year after their initial infection. Researchers found that the health-related quality of life scores for these patients were significantly lower than normal, with average scores on a health survey 40-50% below the expected levels. Additionally, factors such as being female, having other health conditions, or having been treated with corticosteroids were linked to lower quality of life scores, while higher mental health scores were reported by previously hospitalized patients. Who this helps: This benefits patients recovering from COVID-19 and healthcare providers who support them.

Plain English
This study looked at combining two treatments, amivantamab and lazertinib, to see how well they work for patients with a specific type of lung cancer that had already become resistant to standard treatments. Among 45 patients tested, 36% showed a positive response, meaning their cancer shrank or stabilized, with an average treatment effect lasting about 9.6 months. Finding effective treatments for this hard-to-treat cancer is crucial because current options are limited for these patients. Who this helps: This helps patients with advanced lung cancer who have exhausted standard treatment options.

Plain English
This study looked at how the levels of two hepatitis C medications, sofosbuvir and daclatasvir, in the blood of patients with both HIV and hepatitis C are affected by factors like kidney and liver function. The researchers found that higher levels of the sofosbuvir metabolite were linked to slightly worsened kidney function, while higher levels of daclatasvir were associated with more severe liver damage. These findings are important because they help doctors understand how these drugs work in patients who have both infections, which could improve treatment decisions. Who this helps: This helps doctors treating patients with both HIV and hepatitis C.

Plain English
This study looked at how people living with HIV (PLWH) fare when hospitalized with COVID-19 compared to those without HIV. It involved 1,647 patients, with 43 being PLWH. The findings showed that PLWH were younger and had less severe symptoms upon hospitalization, resulting in a lower chance of needing invasive ventilation or dying—4.7% for PLWH compared to 18.9% for non-PLWH after 15 days. Who this helps: This research benefits patients living with HIV and healthcare providers managing their care during COVID-19.

Plain English
This study looked at how well people living with HIV (PLWH) responded to COVID-19 vaccines based on their current T-cell levels. Researchers found that after receiving a booster dose, 86.7% of people with low T-cell counts (less than 200 cells/mm3) developed detectable antibodies, compared to 100% of those with intermediate levels (200-500 cells/mm3) and 98.7% of those with high levels (more than 500 cells/mm3). This is important because it shows that individuals with lower T-cell counts have a weaker immune response to the vaccine, which may put them at higher risk for COVID-19. Who this helps: This helps patients living with HIV, especially those with low T-cell counts.

Plain English
This research studied how two different treatments for newly diagnosed HIV patients—one using four drugs and the other using three—affected their health over time. The study found that both treatment groups had a similar success rate in reducing the virus to undetectable levels (around 76% achieved this after 48 weeks), and their immune recovery was also comparable. This matters because it shows that both treatment options are effective, giving doctors flexibility in prescribing based on individual patient needs. Who this helps: This benefits patients with newly diagnosed HIV.

Plain English
This study looked at how patients with advanced HIV responded to COVID-19, focusing on their immune response and inflammation levels during a SARS-CoV-2 outbreak in a care facility. Researchers found that 90% of patients developed antibodies and showed strong specific T-cell responses, indicating effective immunity against the virus, despite 10% of patients experiencing mild to moderate illness and a mortality rate of 10%. Importantly, the HIV-infected patients had lower levels of certain inflammatory markers compared to those without HIV, suggesting that HIV did not worsen their inflammation or immune response to COVID-19. Who this helps: This research benefits healthcare providers and patients with advanced HIV by improving understanding of their COVID-19 risks and immune responses.

Plain English
This research paper discusses a new Italian Fund dedicated to Alzheimer's disease and other types of dementia, which was established with a budget of 15 million euros over three years. The fund aims to enhance public health strategies for dementia through eight key activities, including the development of care guidelines, updating national plans, promoting prevention, training healthcare workers, and creating a national electronic record for patients. This initiative is crucial as it aims to improve support for patients and their families while addressing the ongoing challenges of dementia care. Who this helps: This helps patients with dementia and their caregivers.

Plain English
This study looked at patients with severe COVID-19 in a hospital in Rome and found that a serious condition called ilio-psoas haematoma (IPH) occurred in seven of them during their treatment, which is a rate of 7.6 cases for every 1,000 COVID-19 patients admitted. This condition often happens as a complication of blood-thinning treatments that are used to prevent clots in critically ill patients. It's crucial for healthcare providers to be aware of this risk because IPH can lead to severe complications and requires prompt attention. Who this helps: This information helps doctors treating severe COVID-19 patients.

Plain English
This study looked at how treating hepatitis C (HCV) affects immune cells in patients who are also living with HIV. Researchers found that eradicating HCV with a specific treatment did not change the levels of CD4 cells, which are important for a healthy immune system, but there was a notable decrease in another type of immune cell, CD8, in patients treated without ribavirin—a drug used in some therapies. This is important because it suggests that clearing HCV can help reduce immune system activation in certain patients, potentially improving their overall health. Who this helps: This benefits patients living with both HIV and HCV, particularly those receiving treatment without ribavirin.

Plain English
Researchers studied the length of time COVID-19 patients continued to shed the virus in their respiratory samples after being hospitalized. They found that on average, patients shed the virus for 18 days, and those who recovered from the virus had a 70.2% chance of being clear of it within 30 days. The study highlighted that patients with existing health issues, severe respiratory symptoms, or delayed hospital visits were less likely to recover quickly, making it crucial for symptomatic patients to seek medical attention early. Who this helps: This helps patients with COVID-19 and their healthcare providers.

Plain English
This study looked at people with HIV who stopped attending their medical appointments for at least 18 months and then returned to care. Out of over 11,000 individuals, about 3,962 became lost to care, and 1,062 re-engaged. It was found that those who re-entered with higher levels of the virus in their blood faced a greater risk of worsening health compared to those who stayed in consistent care, showing that it’s important to encourage regular medical visits for better health outcomes. Who this helps: This benefits patients with HIV, particularly those struggling to stay engaged in their healthcare.

Plain English
This study looked at how testosterone levels affect the severity of COVID-19 in men. Researchers compared 48 male patients, half with severe cases who needed breathing support and half with mild cases, and found that those with severe COVID-19 had much lower testosterone levels—1.4 ng/mL compared to 3.5 ng/mL in those with mild cases. This is important because low testosterone was linked to worse inflammation and longer hospital stays, meaning that measuring testosterone could help identify patients at higher risk for severe illness. Who this helps: This helps doctors treat male COVID-19 patients by identifying those who may need closer monitoring and support.

Plain English
This study looked at whether a treatment called prophylactic low molecular weight heparin (pLMWH) could help COVID-19 patients with mild to moderate pneumonia avoid serious outcomes like needing a breathing tube or dying. Out of 449 patients studied, the chance of intubation or death was about 9.5% for those not taking pLMWH and 10.4% for those who were, showing that pLMWH did not lower these risks significantly. The findings suggest that pLMWH might not be effective for patients whose breathing has already worsened. Who this helps: This study helps doctors understand the limits of pLMWH in treating certain COVID-19 patients.

Plain English
This study looked at a new treatment called amivantamab for patients with a specific type of non-small-cell lung cancer that has a mutation known as EGFR Exon 20 insertion. Among 81 patients treated, 40% responded positively to the treatment, with responses lasting an average of about 11 months, and patients lived without cancer progression for around 8.3 months on average. This is significant because it offers hope for effective treatment options for patients who have not responded to standard chemotherapy. Who this helps: Patients with EGFR Exon 20 insertion-mutated non-small-cell lung cancer.

Plain English
This study looked at the effects of combining two cancer treatments, daratumumab and atezolizumab, in patients with advanced lung cancer who had been previously treated. Researchers found that the combination did not work better than using atezolizumab alone: only 4.3% of patients responded well to the combination compared to 13% for atezolizumab by itself, and there were no significant improvements in survival rates. This matters because it indicates that adding daratumumab does not enhance treatment outcomes for these patients. Who this helps: This helps doctors and researchers understand which treatment combinations may not be effective for lung cancer patients.

Plain English
This study looked at how different Asian populations living in areas where malaria is common have adapted to the disease. Researchers found 285 specific genes that show strong evidence of helping these populations survive malaria, with most of these genes being unique to individual groups. Understanding these adaptations could lead to new treatments or prevention methods for malaria, especially in regions where the disease is prevalent. Who this helps: This helps patients in malaria-endemic areas and researchers working on malaria treatments.

Plain English
This study looked at how food affects the way a medication called cefuroxime axetil is processed in Beagle dogs. Researchers found that when the dogs ate, the amount of medicine absorbed into their bloodstream increased significantly, with absorption rates improving by about 33% for tablets. In contrast, while the suspension form of the drug showed better absorption speed after feeding, both forms were found to last a shorter time in the dogs' blood than hoped, which might limit their effectiveness in treating infections. Who this helps: This research benefits veterinarians and pet owners by providing insights into how to optimize medication administration for dogs.

Plain English
This study looked at how a specific energy production process in cancer cells, called glycolysis, affects the survival of patients with advanced stomach cancer treated with a combination of two drugs, paclitaxel and ramucirumab. Researchers found that in 40 patients, those whose tumors had high levels of glycolysis (18 patients) had significantly worse survival rates compared to those without this metabolic profile. This matters because understanding the connection between glycolysis and cancer progression can help doctors better predict patient outcomes and tailor treatment strategies. Who this helps: Patients with advanced gastric cancer.

Plain English
This study looked at how HIV spreads among people living in Italy, comparing native Italians to migrants from 1998 to 2018. Researchers found that out of 3,499 people, 726 (or about 20.8%) were part of 228 groups where the virus was transmitted, with natives being the majority. It matters because understanding these transmission patterns helps public health officials develop better strategies to prevent the spread of HIV. Who this helps: This helps patients and public health officials target prevention efforts more effectively.

Plain English
This study looked at a type of immune cell called myeloid-derived suppressor cells (MDSCs) in 128 patients infected with COVID-19. It found that levels of a specific type of MDSC, known as PMN-MDSC, were higher in patients who did not survive the illness compared to those who did, indicating a link between these cells and fatal outcomes. The presence of PMN-MDSC was associated with higher levels of inflammatory markers and reduced T-cell activity, which could hinder the body's ability to fight the virus. Who this helps: This research benefits patients by identifying new factors that could predict severe COVID-19 cases, guiding better treatment strategies.